Erythropoetin (EPO) antibody and antigen (hapten, BSA/OVA conjugated)

Diagnostic anti-Erythropoetin (EPO) antibodies (anti-Erythropoetin, anti-EPO) and diagnostic hapten-carrier conjugates BSA-Erythropoetin (EPO), OVA-Erythropoetin (EPO), KLH-Erythropoetin (EPO) antigens for Hormone disorders EPO detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Neurodegenerative diseases diagnostics products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-SMT-EPO-Ag01 BSA-Erythropoetin (EPO) 756
GMP-SMT-EPO-Ag02 OVA-Erythropoetin (EPO) 756
GMP-SMT-EPO-Ab01 Anti-human Erythropoetin (EPO) mouse monoclonal antibody (mAb) 1953
GMP-SMT-EPO-Ab02 Anti-human Erythropoetin (EPO) human monoclonal antibody (mAb) 1953

Size: 1mg | 10mg | 100mg



Product Description

Cat No. of Products GMP-SMT-EPO-Ag01
Product Name BSA-Erythropoetin (EPO)
Target/Biomarker Erythropoetin (EPO)
Expression platform Synthetic
Isotypes NA
Bioactivity validation Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag NA
Products description Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity Purity: ≥95% (SDS-PAGE)
Application Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products GMP-SMT-EPO-Ag02
Product Name OVA-Erythropoetin (EPO)
Target/Biomarker Erythropoetin (EPO)
Expression platform Synthetic
Isotypes NA
Bioactivity validation Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag NA
Products description Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity Purity: ≥95% (SDS-PAGE)
Application Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products GMP-SMT-EPO-Ab01
Product Name Anti-human Erythropoetin (EPO) mouse monoclonal antibody (mAb)
Target/Biomarker Erythropoetin (EPO)
Expression platform Hybridoma
Isotypes Mouse IgG
Bioactivity validation Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag mFc
Products description Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity Purity: ≥95% (SDS-PAGE)
Application Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products GMP-SMT-EPO-Ab02
Product Name Anti-human Erythropoetin (EPO) human monoclonal antibody (mAb)
Target/Biomarker Erythropoetin (EPO)
Expression platform Hybridoma
Isotypes Mouse IgG
Bioactivity validation Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation.
Tag mFc
Products description Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic.
Purity Purity: ≥95% (SDS-PAGE)
Application Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker information

    Erythropoietin (EPO) is produced and released into the blood by the kidneys in response to low blood oxygen levels (hypoxemia). The amount of erythropoietin released depends on how low the oxygen level is and the ability of the kidneys to produce erythropoietin. EPO is carried to the bone marrow, where it stimulates production of red blood cells. The hormone is active for a short period of time and then eliminated from the body in the urine. However, if kidneys are damaged and do not produce enough erythropoietin, then too few RBCs are produced and leads to anemic. Similarly, if bone marrow is unable to respond to the stimulation from EPO also become anemic. This can occur with some bone marrow disorders or with chronic diseases, such as rheumatoid arthritis. The erythropoietin production increased with some benign or malignant kidney tumors and with a variety of other cancers, it also produces too many RBCs  (polycythemia or erythrocytosis). This can lead to an increase in the blood’s thickness (viscosity) and sometimes to high blood pressure (hypertension), blood clots (thrombosis), heart attack, or stroke. Rarely, polycythemia is caused by a bone marrow disorder called polycythemia vera, not by increased erythropoietin.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.

    Comments


    No comments yet.

    Leave a comment